The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), awarded Nuago Therapeutics Inc. a $400,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to develop a novel, RNA-interference-based therapeutic to treat prostate cancer. The funding will support research to evaluate the uptake and activity of the therapy, named "NU002", in mouse models of prostate cancer, and characterize its anti-tumor effects in vivo. This Phase I work is expected to provide proof-of-concept data to support future preclinical and clinical development of the therapy, which is based on short interfering RNA molecules derived from CAG trinucleotide repeat sequences. The goal is to leverage this naturally occurring anti-cancer mechanism to treat prostate cancer, an area of significant unmet medical need.
Generated 3/4/25, 8:11 AM